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Background: Fatigue is a complex and disabling symptom of Multiple Sclerosis (MS); 
however, there is conflicting evidence of the relationship between fatigue and clinical 
features of MS. Furthermore, few studies have considered these relationships specifically in a 
progressive MS population.  
Aims: (1) estimate the prevalence of self-reported fatigue in people with MS; (2) evaluate the 
relationship between fatigue severity/impact and clinical features of MS; (3) compare the 
prevalence of fatigue, and the strength of relationship between fatigue severity/impact and 
clinical features of MS in progressive and non-progressive forms of MS. 
Methods: An online survey was conducted to measure the severity (Fatigue Severity Scale 
(FSS)) and impact of self-reported fatigue (Modified Fatigue Impact Scale) in people with 
MS. The survey also contained questionnaires related to disability, quality of life, MS impact, 
anxiety and depression, cognition, and sleep quality.  
Results: 412 people responded to the survey, of which 68.7% reported having fatigue 
(FSS≥5). The prevalence of fatigue was significantly higher in participants with progressive 
MS (81%) in comparison to those with non-progressive forms of MS (64%, p=0.01). Fatigue 
severity and impact were associated with quality of life, MS impact, anxiety, depression, 
cognition, and sleep quality in both progressive and non-progressive MS populations 
(p<0.05). However, fatigue severity (r = 0.335) and impact (r = 0.391) were correlated with 
disability only in participants with non-progressive MS.  
Conclusion: Fatigue was more prevalent amongst participants with progressive MS. In 
addition, higher fatigue severity and impact were associated with greater physical, cognitive, 
and psychological impairment, although the strength of association between these outcomes 
was generally similar regardless of the type of MS.   
 




1.  Introduction 
Fatigue is a complex and multifactorial symptom of Multiple Sclerosis (MS) which can be 
defined as “a subjective lack of physical and/or mental energy that is perceived by the 
individual or caregiver to interfere with usual and desired activities” [1]. It is often regarded 
as the most debilitating symptom of MS which impacts upon cognitive, psychological, and 
physical functioning [2], while also leading to reduced quality of life and unemployment 
[3,4]. Estimates of fatigue prevalence range between 52%-88%, making it one of the most 
common symptoms of MS [5-13]. However, differences in study populations and outcome 
measures, and differences in the methods used to identify people with or without fatigue 
explain the large variation in the reported prevalence of fatigue between studies.  
 
While the exact pathophysiological mechanisms of MS-fatigue remain unknown, there is 
evidence to suggest that fatigue is a direct consequence of the primary pathological 
mechanisms of MS including inflammation and neurological damage [14]. In addition, 
secondary mechanisms independent of MS pathophysiology such as depression or disability 
may contribute to the development of fatigue [15]. However, studies investigating the 
association of fatigue with concomitant clinical and demographic features have presented 
conflicting results. For example, several cross-sectional [8, 13, 16, 17] and longitudinal 
studies [18-21] have demonstrated an association between fatigue and depression, while other 
studies have demonstrated that fatigue occurs independently of depression [6, 22, 23]. 
Similarly, there is limited consensus regarding the relationship between fatigue and disability 
[8, 11, 13, 23, 24], and fatigue and demographic variables such as age, sex, and disease 
duration [6, 9, 23, 25]. Furthermore, few studies have considered the relationship between 
fatigue and sleep quality [26-28], or cognition [17, 29] – symptoms which are common in MS 
[30, 31], and have been suggested to contribute to the development of fatigue [14].  
 
Although fatigue is more prevalent in progressive forms of MS [10, 19, 23], few studies have 
considered the association between fatigue and relevant clinical features specifically in 
progressive MS populations (secondary progressive MS (SPMS) and primary progressive MS 
(PPMS)). Therefore, further work is required to understand which clinical and demographic 
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features are associated with fatigue to inform the design and evaluation of fatigue 
management interventions for people with progressive MS. Hence, this study aims to: (1) 
estimate the prevalence of self-reported fatigue in people with MS; (2) evaluate the 
relationship between fatigue severity and impact and clinical features of MS and; (3) compare 
the prevalence of fatigue and the relationships in (2) in progressive and non-progressive MS.   
 
2. Methods  
2.1. Design and participant recruitment 
This cross-sectional study collected data using an online survey made available for one 
month between May 30th-June 30th 2018. The open-access survey was designed using 
RedCap software v6.15 [32] and was accessed via a link distributed online to potential 
participants through information shared by national and international MS charities and 
organisations based in the UK, USA, and Australia. Prior to accessing the survey, participants 
were required to confirm they had a medical diagnosis of MS and were aged 18 years or 
older. Participants self-reported demographic information (including MS type and disability 
using the Patient Determined Disease Steps (PDDS)) [33, 34], and completed a series of 
patient-reported outcome measures related to fatigue, MS impact, quality of life, depression 
and anxiety, cognition, and sleep. The survey took approximately 30-40 minutes to complete, 
and participants were allowed to save responses and return to the survey at a later time. 
Ethical approval for this study was obtained from Glasgow Caledonian University School of 
Health and Life Sciences Ethics Committee.  
 
2.2. Outcome measures 
2.2.1. Fatigue  
Fatigue severity was assessed using the Fatigue Severity Scale (FSS). The FSS is a seven-
point ordinal scale where participants rate the severity of fatigue in response to nine items, 
with total scores ranging between 0-7 [35]. The FSS has demonstrated moderate test-retest 
reliability and high precision in MS populations [24, 36, 37], and has strong internal 
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consistency [38]. In line with previous studies, participants that scored ≥5 on the FSS were 
classified as fatigued [8, 10, 17-19, 21, 25].  
 
Fatigue impact was measured using the Modified Fatigue Impact Scale (MFIS). The MFIS is 
a multidimensional scale that evaluates the impact of fatigue on physical, cognitive, and 
psychosocial domains [25]. The MFIS contains 21 items (nine physical, ten cognitive, and 
two psychosocial) with a five-point ordinal scale (maximum score of 84), and requires 
participants to recall the impact of fatigue, with higher scores indicating a greater impact of 
fatigue [25]. The MFIS is widely used in MS populations, and has strong validity and test-
retest reliability [24, 36, 37, 39]. 
 
2.2.2. MS impact 
MS impact was assessed using the MS Impact Scale-29 (MSIS-29) version one, a valid and 
reliable disease specific questionnaire which assesses the physical and psychological impact 
of MS over 29 items using an ordinal scale [40-42]. Physical and psychological subscale 
scores range between 20-100 and 9-45 respectively, with higher scores indicating greater 
impact of MS.  
 
2.2.3. Quality of life 
Quality of life was assessed using the EQ-5D-3L, which consists of five domains – mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression – and generates a health 
index (EQ-5Dindex) with a maximum score of 1 indicating ‘full health’ [43]. The weighted 
health index was calculated using the UK value set [44]. The EQ-5D-3L also captures self-
reported health status (EQ-5Dstatus) using a visual analogue scale ranging between 0 (worst 
imagined health state) and 100 (highest health state). 
 
2.2.4. Anxiety and depression 
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Anxiety and depression were measured using the Hospital Anxiety and Depression Scale 
(HADS). The HADS consists of separate anxiety and depression scales that are comprised of 
seven items – scores range between 0-21 with higher scores indicating greater severity of 
anxiety or depression [45]. The validity of the HADS has been demonstrated in MS 
populations [46].  
 
2.2.5. Cognition 
Cognition was assessed using the MS Neuropsychological Screening Questionnaire 
(MSNSQ) – a valid screening tool for cognitive dysfunction in people with MS which has 
been shown to correlate with Symbol Digit Modalities Test scores [47-49]. Participants rate 
the impact and severity of problems with attention, memory, processing speed, emotional 
control, and social skills across 15 items using an ordinal scale [47]. Scores range from 0-60, 
with higher scores indicating greater cognitive dysfunction.  
 
2.2.6. Sleep quality 
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item 
questionnaire comprised of seven components: subjective sleep quality, sleep latency, sleep 
duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication and 
daytime dysfunction during the previous month [50]. Scores range from 0-21, with higher 
scores indicating poorer sleep quality. Validity of the PSQI has been demonstrated in clinical 
populations [51], and the PSQI has been used in other MS studies [17, 24]. 
 
2.3. Data analysis  
Data analysis was performed using IBM SPSS v23 (IBM Corporation, Armonk, NY, USA). 
Survey responses of participants who provided complete demographic information and FSS 
scores were included in the data analysis, and missing data were excluded from subsequent 
analysis using pairwise deletion. The prevalence of fatigue (percentage of people who 
reported FSS≥5), mean questionnaire scores, and participant demographics were compared 
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between those with progressive and non-progressive forms of MS (relapsing-remitting MS 
(RRMS), Benign MS, or an unknown form of MS) using Chi-square tests for categorical 
variables and unpaired t-tests for continuous variables as data were normally distributed 
according to the Shapiro-Wilk statistic. Pearson correlation coefficients were used to assess 
the relationship of the FSS and MFIS with questionnaire responses (MSIS-29, EQ-5D, 
HADS, MSNSQ, PSQI) and demographic variables (disability, disease duration, age) – 
correlation coefficients <0.3 were interpreted as weak, ≥0.3 to <0.7 as moderate, and ≥0.7 as 
strong [52]. Subsequently, correlation coefficients were compared between people with 
progressive non-progressive MS using z values derived from Fisher’s transformation [53]. 
Finally, two separate multiple linear regression analyses were performed using FSS (fatigue 
severity) and MFIS (fatigue impact) as the dependent variables for both progressive MS and 
non-progressive MS populations. Independent variables (FSS/MFIS (total score), age, time 
since diagnosis, PDDS, EQ-5Dindex, MSIS-29, HADS, MSNSQ, and PSQI) were entered 
using stepwise backwards elimination methods with probability values of ≤0.05 for variable 
entry and ≥0.10 for variable removal. For all tests, a significance level of p<0.05 was used.  
 
3. Results 
3.1. Demographic data and fatigue prevalence  
Of the 498 people who participated in the survey, 412 (83%) provided full demographic data 
and FSS scores and were included in the analysis (Table 1). In total 308 participants (75%) 
provided complete survey responses. 111 (27%) participants reported having a progressive 
form of MS (SPMS = 74, PPMS = 37), whereas 301 (73%) reported having a non-progressive 
form (RRMS = 291, benign MS = 2, unknown type = 8). Participants were mostly female 
(81.3%) and had a mean (SD) age of 46 years (11.5) and time since diagnosis of 9.6 years 
(8.6). People with progressive MS were significantly older (p<0.001), had a longer time since 
diagnosis (p<0.001), reported higher levels of disability (p<0.001), and had a higher 
proportion not in employment (p<0.001) in comparison to participants with non-progressive 
MS (Table 1).  
 




The prevalence of fatigue was significantly higher amongst participants with progressive MS 
(81.1%, 95% CI = 72.8-87.3) compared to the non-progressive MS population (64.1%, 95% 
CI = 58.6-69.3) (Table 2). In addition, participants with progressive MS reported greater 
fatigue severity (FSS = 5.6±1.3, p=0.012), and greater physical (MFIS (physical) = 27.8±6.1, 
p<0.001) and psychosocial impact of fatigue (MFIS (psychosocial) = 5.7±1.8, p = 0.009). 
However, mean MFIS (total) (p = 0.149) did not differ between participants with progressive 
or non-progressive MS. Across the other outcome measures, participants with progressive 
MS reported lower quality of life (p<0.001), and higher depression (p<0.001) and physical 
impact of MS (p<0.001) (Table 2). There were no differences between the progressive MS 
and non-progressive MS populations in cognition (MSNSQ, p = 0.2), impact of fatigue on 
cognition (MFIS (cognition), p = 0.371), psychological impact of MS (p = 0.924), anxiety (p 
= 0.667) and sleep quality (p = 0.416).  
 
Table 2 (near here) 
 
3.2. Correlation of fatigue severity with clinical variables  
In the total study population, fatigue severity (FSS) was moderately correlated with fatigue 
impact (MFIS total) (r = 0.646, p<0.001) in addition to the physical (r = 0.690, p<0.001), 
cognitive (r = 0.451, p<0.001), and psychosocial (r = 0.616, p<0.001) subscales of the MFIS 
(Table 3). Furthermore, FSS scores demonstrated moderate correlation with quality of life 
(EQ-5Dindex: r = -0.330, p<0.001; EQ-5Dstatus: r = -0.415, p<0.001), MS impact (MSIS-29 
(physical): r = 0.547, p<0.001; MSIS-29 (psychological): r = 0.466, p<0.001), depression 
(HADS (depression): r = 0.364, p<0.001), and cognition (MSNSQ: r = 0.321, p<0.001), and 
weak correlation with anxiety (HADS (anxiety): r = 0.234, p<0.001) and sleep quality (PSQI: 
r = 0.288, p<0.001). There was no relationship between fatigue severity and time since 




There were few significant differences when comparing the strength of correlation between 
fatigue severity and clinical variables in the progressive MS and non-progressive MS 
populations. However, PDDS was moderately correlated with FSS scores in the non-
progressive MS population (r = 0.335, p<0.001) and demonstrated no association with fatigue 
severity in those with progressive MS (r = 0.092, p = 0.335). For all other correlation 
coefficients, there was no difference between participants with progressive and non-
progressive forms of MS (p>0.05). 
 
Table 3 (near here) 
 
3.3. Correlation of fatigue impact with clinical variables 
Fatigue impact (MFIS (total)) demonstrated moderate to strong correlation with quality of life 
(EQ-5Dindex: r = -0.542, p<0.001; EQ-5Dstatus: r = -0.516, p<0.001), MS impact (MSIS-29 
(physical): r = 0.660, p<0.001; MSIS-29 (psychological): r = 0.721, p<0.001), anxiety 
(HADS (anxiety): r = 0.442, p<0.001), depression (HADS (depression): r = 0.559, p<0.001), 
cognition (MSNSQ: r = 0.665, p<0.001), and sleep quality (PSQI: r = 0.438, p<0.001) in the 
total study population (Table 4).  
 
In the progressive MS population, age was negatively correlated with fatigue impact (r = -
0.236, p = 0.014), and HADS (anxiety) had a significantly stronger association with fatigue 
impact in comparison to those with non-progressive MS (r = 0.578 vs. 0.388, p = 0.037). 
Conversely, in the non-progressive MS population PDDS was moderately correlated with 
fatigue impact (r = 0.391, p<0.001) and MSIS-29 (physical) was more strongly associated 
with fatigue impact in comparison to the progressive MS population (r = 0.747 vs. 0.599, p = 
0.02). All other correlation coefficients were comparable between the progressive and non-
progressive MS populations (p>0.05).  
 




3.4. Variables predicting fatigue severity and impact  
In participants with progressive MS, MFIS (total) scores were the strongest predictor of 
fatigue severity (β = 0.816, p<0.001) (Table 5). In addition, MSIS-29 (psychological) (β = 
0.309, p = 0.053), HADS (anxiety) (β = -0.249, p = 0.05), and MSNSQ (β = -0.290, p<0.001) 
predicted an increase in fatigue severity; although MSIS-29 (psychological) and HADS 
(anxiety) did not reach the threshold for statistical significance (p<0.05). Overall, these 
variables accounted for 55.7% (R
2
 = 0.557) variance in FSS scores (F(4, 78) = 24.5, 
p<0.001). 
 
Similarly, fatigue impact was a strong predictor of FSS score in participants with non-
progressive MS (β = 0.566, p<0.001), while EQ-5Dindex (β = 0.117, p = 0.086), MSIS-29 
(physical) (β = 0.279, p = 0.001), and MSNSQ (β = -0.124, p = 0.071) also contributed to the 
prediction of fatigue severity, with this model accounting for 43.3% (R
2
 = 0.433) variance in 
FSS scores (F(4, 220) = 42, p<0.001). However, only the MFIS and MSIS-29 (physical) were 
significant predictors of FSS scores in this model (p<0.05). 
 
Table 5 (near here) 
 
FSS scores predicted fatigue impact in both the progressive MS (β=0.428, p<0.001) and non-
progressive MS populations (β = 0.248, p<0.001) (Table 6). In the progressive MS 
population, EQ-5Dindex (β = -0.109, p = 0.09), MSIS-29 (psychological) (β = 0.230, p = 0.01), 
and MSNSQ (β = 0.349, p<0.001) also predicted fatigue impact, accounting for 77% (R2 = 
0.77) variance in MFIS (total) scores (F(4,78) = 65.4, p<0.001); whereas in participants with 
non-progressive MS, MSIS-29 (physical) (β = 0.305, p<0.001), MSIS-29 (psychological) (β 
= 0.269, p<0.001), HADS (anxiety) (β = -0.106, p = 0.032), and MSNSQ (β = 0.320, 
p<0.001) accounted for 74.4% (R
2





Table 6 (near here) 
 
4. Discussion 
This large cross-sectional study found that fatigue was a prevalent symptom of MS, reported 
in 68.7% of the population. In addition, a higher proportion of participants with progressive 
MS (81.1%) reported fatigue compared to those with non-progressive forms of MS (64.1%), 
which confirms evidence from previous studies that fatigue is more prevalent amongst people 
with progressive forms of the disease [13, 19, 23]. Furthermore, in terms of the correlation 
between fatigue and clinical features of MS, both fatigue severity and impact were associated 
with higher levels of disability, poorer quality of life, greater depression and anxiety, and 
poor cognition and sleep quality. However, despite fatigue being more prevalent and severe 
in participants with progressive MS, the strength of association between fatigue 
severity/impact and the clinical features examined was generally comparable between the 
progressive MS and non-progressive MS populations. 
 
Due to the different outcome measures and criteria used to define those with/without fatigue, 
it is difficult to directly compare the prevalence of fatigue in this progressive MS population 
with previously reported estimates of fatigue prevalence. However, the overall proportion of 
participants who reported fatigue in this study (68.7%) is higher than other studies that 
defined fatigue using the same methods (FSS≥5), with estimates of prevalence reported as 
54% [21], 55% [18], 58% [17], and 65% [8]. Heterogeneity in MS type between studies may 
account for some difference in the reported estimates of fatigue prevalence – for example, the 
study by Bakshi et al. [8] did not include people with PPMS, whereas the study by Andreasen 
et al. [17] only included people with RRMS. Nevertheless, despite differences in estimates of 
prevalence, this study confirms that fatigue is a common symptom of MS and highlights the 





The exact mechanisms of fatigue in MS have still to be fully elucidated, but are likely to 
include issues with inflammation and function of demyelinated nerve pathways in addition to 
secondary factors (e.g. clinical features such as depression and disability) independent of the 
primary MS pathophysiology [14, 15]. While several studies have investigated the 
association between fatigue and relevant outcomes, results remain equivocal with the 
presence and strength of association varying between studies. However, the findings from the 
overall study population confirm the results from previous studies that demonstrate fatigue is 
associated with physical [11, 13, 24], psychological [20, 21], and cognitive outcomes [17, 29] 
and, therefore, highlight the multifactorial and debilitating impact of fatigue in MS.  
 
While causality cannot be inferred from these results, it is likely that fatigue is associated 
with these outcomes in a bi-directional relationship, as higher levels of fatigue could be the 
cause or consequence of impaired physical, cognitive, and psychological functioning [15]. 
For example, fatigue is often considered symptomatic of depression, although depression 
may develop as a result of fatigue and the resultant impact on daily living [20]. Similarly, 
mobility impairments may induce fatigue due to increased energy expenditure, whereas 
fatigue may limit mobility due to restrictions in physical activity [15]. Accordingly, 
longitudinal studies are required to establish the potential causal association between these 
outcomes and fatigue to improve fatigue management strategies for both progressive and 
non-progressive MS populations.   
 
A novel finding of this study was that the strength of association between fatigue 
severity/impact and clinical features of MS were generally comparable between the 
progressive MS and non-progressive MS populations. However, there were a few exceptions 
as fatigue severity and impact were only correlated with disability in the non-progressive MS 
population, whereas fatigue impact was more strongly correlated with age and anxiety in the 
progressive MS population. Therefore, cognitive and psychological outcomes should be 
given greater prominence when designing and evaluating fatigue management interventions 
for people with progressive MS, as they were more strongly associated with fatigue in 
comparison to physical outcomes. Conversely, disability and physical outcomes may have 




Interestingly, in both the progressive and non-progressive MS populations, the clinical 
features examined in this study were more strongly associated with fatigue impact (MFIS) in 
comparison to fatigue severity (FSS). This result may suggest that the MFIS is a more 
sensitive measure of MS-related fatigue due to the multidimensional nature of fatigue and 
ceiling effect of the FSS [38, 55]; however, it may also reflect the content validity of the 
MFIS and the limited ability to distinguish between global levels of function (e.g. physical, 
cognitive and psychosocial function) and the impact of fatigue on these domains [56]. 
Alternatively, outcomes other than those included in this study may be associated with the 
development and severity of fatigue – such as the primary disease mechanisms of MS. For 
example, it has been suggested that inflammation is associated with the development of 
fatigue, with levels of inflammatory biomarkers (interferon γ and tumour necrosis factor α) 
correlating with fatigue in MS [57, 58] – although this association may have limited 
relevance to progressive MS due to the absence of a marked inflammatory response [59, 60]. 
Additionally, structural neurological damage – including cortical atrophy and grey matter 
lesions – and patterns of neural re-organisation have also been found to be associated with 
fatigue in MS [15, 57]. However, further longitudinal studies are required to determine the 




Due to the cross-sectional nature of this study, it was not possible to determine causality in 
the relationship between fatigue and the selected clinical and demographic variables. In 
addition, although the FSS and MFIS were selected to independently measure the severity 
and impact of fatigue, the strong association between these outcome measures may suggest 
they measure related aspects of fatigue. Furthermore, as data were collected through an open 
online survey, our study population may have been biased towards people experiencing 
fatigue, and was limited to those who were able to access the internet which potentially 
excluded those with more severe disabilities (for example, advanced cognitive, visual or 
physical impairments). In addition, the study design dictated that self-reported outcome 
measures were used to assess all clinical features; therefore, although the MSNSQ has limited 
reliability in measuring cognitive function (particularly in people with depression and 
cognitive impairment) [48], it was included in this study as it could be feasibly used as a self-
reported outcome measure and provides a quick and valid estimation of cognitive function 
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[47]. However, the online nature of this study enabled a large international population to be 
recruited, and although MS diagnosis and type were self-reported, the participant 
demographics of this study sample were representative of a typical MS population [61, 62]. 
Lastly, as the number of potentially eligible participants was unknown, it was not possible to 
determine the survey response rate.  
 
5. Conclusions 
To our knowledge, this was the first study to compare the association between fatigue 
severity/impact and selected clinical and demographic variables in people with progressive 
and non-progressive forms of MS. This study confirmed that fatigue is a common symptom 
of MS, and that fatigue is more prevalent and severe amongst those with progressive MS. In 
addition, fatigue severity and impact were found to correlate with quality of life, MS impact, 
depression, anxiety, cognition, and sleep quality, and the strength of these relationships were 
similar in participants with progressive and non-progressive forms of MS. Therefore, this 
study highlights the multifactorial nature of fatigue and the importance of considering these 
outcomes as potential mediator or moderator variables when comprehensively designing and 
evaluating interventions aimed at improving fatigue. Furthermore, these associations may 
underline potential causal pathways of fatigue in both progressive and non-progressive forms 
of MS, and justifies the need for longitudinal assessment to explore the mechanisms of MS-
related fatigue. 
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PPMS, n=37; total, 
n=111) 
Non-progressive 
MS (RRMS, n=291; 
Benign MS, n=2; 
unknown, n=8; total, 
n= 301) 
p 
Age (years), mean ± 
SD (range) 
46 ± 11.5 (22-79) 56 ± 8.9 (30-79)  42 ± 10.1 (22-69) < 0.001 
Time since 
diagnosis (years), 
mean ± SD (range) 
9.6 ± 8.6 (0-44) 15.4 ± 10.6 (0-44) 7.4 ± 6.5 (0-36)  < 0.001 
PDDS, mean ± SD 
(range) 
3.1 ± 2.3 (0-8) 5.6 ± 1.4 (2-8)  2.2 ± 1.9 (0-7)  < 0.001 
Sex, % (n) 
    
Female 81.3% (335) 77.5% (86) 82.7% (249) 
0.225 
Male 18.7% (77) 22.5% (25) 17.3% (52) 
Work status, % (n) 
    
Working  47.1% (194) 18% (20) 57.8% (174) 
< 0.001 
Not working  52.9% (218) 82% (91) 42.2% (127) 
Highest level of 
education, % (n) 
    




10.4% (43) 9% (10) 11% (33) 
High school 19.2% (79) 23.4% (26) 17.6% (53) 
Did not complete 
high school  
0.7% (3) 0.9% (1) 0.7% (2) 
Abbreviations: MS, Multiple Sclerosis; PDDS, Patient Determined Disease Steps; PPMS, Primary Progressive 

























     
FSS 5.4 ± 1.4 (n=412)  5.6 ± 1.3 (n=111) 5.2 ± 1.4 (n=301) 0.012 
     
MFIS (total) 54.6 ± 16 (n=385) 56.5 ± 15.8 (n=107) 53.9 ± 16.1 (n=278) 0.149 
MFIS (physical) 25.5 ± 7.3 (n=385) 27.8 ± 6.1 (n=107) 24.7 ± 7.5 (n=278)  < 0.001 
MFIS (cognitive) 23.7 ± 9.1 (n=385)  23 ± 10.3 (n=107) 24 ± 8.6 (n=278) 0.371 
MFIS 
(psychosocial) 
5.4 ± 2 (n=385)  5.7 ± 1.8 (n=107) 5.2 ± 2 (n=278) 0.009 
     
EQ-5Dindex 
0.51 ± 0.34 
(n=375) 
0.33 ± 0.36 (n=105) 0.58 ± 0.3 (n=270)  < 0.001 
     
EQ-5Dstatus 
56.5 ± 22.7 
(n=372)  
49.3 ± 24 (n=104) 59.3 ± 21.5 (n=268) < 0.001 
     
MSIS-29 
(physical) 
61.5 ± 20.1 
(n=365)  
76.1 ± 16.6 (n=102) 55.9 ± 18.5 (n=263) < 0.001 
     
MSIS-29 
(psychological) 
27.8 ± 8.9 (n=365)  27.8 ± 9.2 (n=102) 27.7 ± 8.8 (n=263) 0.924 
     
HADS (anxiety) 8.9 ± 4.7 (n=357) 8.7 ± 5 (n=99) 8.9 ± 4.6 (n=258) 0.667 
     
HADS 
(depression) 
7.9 ± 4.3 (n=357) 9.34 ± 4.5 (n=99) 7.3 ± 4.1 (n=258) < 0.001 
     
MSNSQ 
30.4 ± 14.6 
(n=347) 
28.8 ± 15.3 (n=97) 31 ± 14.3 (n=250) 0.200 
     
PSQI 9.5 ± 4.1 (n=308) 9.2 ± 3.9 (n=83) 9.6 ± 4.2 (n=225) 0.416 
Abbreviations: FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; MFIS, Modified Fatigue 
Impact Scale; MS, Multiple Sclerosis; MSIS-29, Multiple Sclerosis Impact Scale-29; MSNSQ, Multiple Sclerosis 
Neuropsychological Screening Questionnaire; PSQI, Pittsburgh Sleep Quality Index  
Values reported as mean ± SD unless otherwise specified; values in brackets indicate the number of participants who 
completed each questionnaire  





Table 3 Correlation (r) of the Fatigue Severity Scale with clinical and demographic features in the progressive MS and non-progressive MS 
population 
   
FSS 
    
 
Total population (n=412) Progressive MS (n=111) Non-progressive MS (n=301) z† p 
Age 0.096 (-0.012, 0.200) -0.158 (-0.308, 0.001) 0.095 (-0.020, 0.212) -2.27 0.023* 
Time since 
diagnosis 
0.055 (-0.037, 0.150)  -0.067 (-0.253, 0.089) 0.043 (-0.081, 0.163) -0.98 0.327 
PDDS 0.297
***
 (0.199, 0.393) 0.092 (-0.078, 0.264) 0.335
***
 (0.224, 0.445) -2.28 0.022* 
MFIS (total) 0.646
***
 (0.553, 0.726) 0.700
***
 (0.572, 0.801) 0.624
***
 (0.506, 0.729) 1.18 0.235 
MFIS (physical)  0.690
***
 (0.603, 0.766) 0.75
***
 (0.603, 0.866) 0.666
***
 (0.551, 0.769) 1.47 0.142 
MFIS (cognitive) 0.451
***
 (0.347, 0.542) 0.520
***
 (0.368, 0.648) 0.439
***





 (0.529, 0.621) 0.674
***
 (0.513, 0.811) 0.592
***
 (0.489, 0.688) 1.19 0.234 
EQ-5Dindex -0.330
***
 (-0.430, -0.242) -0.275
**
 (-0.446, -0.103) -0.331
***
 (-0.444, -0.202) 0.53 0.596 
EQ-5Dstatus -0.415
***
 (-0.511, -0.317) -0.317
**
 (-0.467, -0.142)  -0.440
***





 (0.457, 0.630) 0.517
***
 (0.329, 0.686) 0.569
***





 (0.365, 0.560) 0.523
***
 (0.340, 0.679) 0.448
***
 (0.320, 0.561) 0.83 0.407 
HADS (anxiety) 0.234
***
 (0.125, 0.339) 0.297
**
 (0.093, 0.490) 0.214
***







 (0.257, 0.457) 0.328
**
 (0.115, 0.527)  0.357
***
 (0.236, 0.470) -0.27 0.787 
MSNSQ 0.321
***
 (0.217, 0.423) 0.350
***
 (0.199, 0.484) 0.325
***
 (0.192, 0.445) 0.23 0.818 
PSQI 0.288
***
 (0.177, 0.399) 0.374
***
 (0.183, 0.544) 0.268
***
 (0.139, 0.393) 0.91 0.363 
Abbreviations: FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; MFIS, Modified Fatigue 
Impact Scale; MS, Multiple Sclerosis; MSIS-29, Multiple Sclerosis Impact Scale-29; MSNSQ, Multiple Sclerosis 
Neuropsychological Screening Questionnaire; PDDS, Patient Determined Disease Steps; PSQI, Pittsburgh Sleep Quality 
Index  
Values reported as Pearson correlation coefficients (95% CI)  
* p <0.05; ** p <0.01; *** p <0.001; otherwise value is not significant (p >0.05) 










      
  Total population (n=385) Progressive MS (n=107) Non-progressive MS (n=278) z† p 
Age -0.007 (-0.128, 0.101) -0.236
*
 (-0.422, -0.062) 0.006 (-0.130, 0.139) -2.14 0.032* 
Time since 
diagnosis 
0.056 (-0.053, 0.152)  0.007 (-0.184, 0.189) 0.040 (-0.090, 0.158) -0.29 0.772 
PDDS 0.291
***
 (0.189, 0.389) 0.090 (-0.073, 0.268) 0.391
***
 (0.280, 0.495) -2.80 0.005** 
FSS 0.646
***
 (0.553, 0.726) 0.700
***
 (0.572, 0.801) 0.624
***
 (0.506, 0.729) 1.18 0.235 
EQ-5Dindex -0.542
***
 (-0.609, -0.471) -0.485
***
 (-0.613, -0.337) -0.585
***
 (-0.654, -0.525) 1.21 0.226 
EQ-5Dstatus -0.516
***
 (-0.587, -0.439) -0.490
***
 (-0.619, -0.346)  -0.526
***





 (0.592, 0.718) 0.599
***
 (0.431, 0.729) 0.747
***





 (0.668, 0.775) 0.752
***
 (0.626, 0.836) 0.711
***
 (0.651, 0.769) 0.75 0.453 
HADS (anxiety) 0.442
***
 (0.345, 0.525) 0.578
***
 (0.408, 0.711) 0.388
***







 (0.391, 0.693) 0.561
***
 (0.476, 0.642) 0.01 0.992 
MSNSQ 0.665
***
 (0.600, 0.722) 0.702
***
 (0.587, 0.786) 0.659
***
 (0.579, 0.724)  0.66 0.509 
PSQI 0.438
***
 (0.339, 0.530) 0.465
***
 (0.266, 0.617) 0.434
***
 (0.314, 0.538) 0.30 0.764 
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Abbreviations: FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; MFIS, Modified Fatigue Impact Scale; MS, Multiple Sclerosis; MSIS-29, 
Multiple Sclerosis Impact Scale-29; MSNSQ, Multiple Sclerosis Neuropsychological Screening Questionnaire; PDDS, Patient Determined Disease Steps; PSQI, 
Pittsburgh Sleep Quality Index  
Values reported as Pearson correlation coefficients (95% CI)  
* p <0.05; ** p <0.01; *** p <0.001; otherwise value is not significant (p >0.05)  





Table 5 Results of regression analysis indicating the variables which predicted Fatigue 





 b (SE) β p  
     (a) 0.557* 
   
Constant 
 
1.810 (0.403) . <0.001 
MFIS (total) 
 
0.690 (0.010) 0.816 <0.001 
MSIS-29 
(psychological)  
0.045 (0.023) 0.309 0.053 
HADS (anxiety) 
 
-0.066 (0.033) -0.249 0.05 
MSNSQ   -0.025 (0.010) -0.290 0.013 
     
(b) 0.433† 
   
Constant 
 
1.378 (0.478) . 0.004 
MFIS (total) 
 
0.051 (0.008) 0.566 <0.001 
EQ-5Dindex  
0.556 (0.323) 0.117 0.086 
MSIS-29 (physical) 
 
0.022 (0.006) 0.279 0.001 
MSNSQ   -0.012 (0.007) -0.124 0.071 
Abbreviations: FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and 
Depression Scale; MFIS, Modified Fatigue Impact Scale; MS, Multiple Sclerosis; 
MSIS-29, Multiple Sclerosis Impact Scale-29; MSNSQ, Multiple Sclerosis 
Neuropsychological Screening Questionnaire 
(a), Progressive MS; (b), Non-progressive MS 
* F(4, 78)=24.5, p<0.001 
    † F(4, 220)=42, p<0.001 




Table 6 Results of regression analysis indicating the variables which predicted Modified 
Fatigue Impact Scale scores in the progressive MS and non-progressive MS populations 
 
MFIS 
 Variables R2 b (SE) β p  
       (a) 0.770* 
   
 Constant 
 
8.089 (4.562) . 0.08 
  EQ-5Dindex  
-4.822 (2.808) -0.109 0.09 
  MSIS-29 
(psychological)  
0.395 (0.150) 0.230 0.01 
  MSNSQ 
 
0.360 (0.078) 0.349 <0.001 
  FSS   5.071 (0.755) 0.428 <0.001 
       (b) 0.744† 
   
 Constant 
 
2.984 (2.287) . 0.193 
  MSIS-29 (physical) 
 
0.265 (0.046) 0.305 <0.001 
  MSIS-29 
(psychological)  
0.492 (0.120) 0.269 <0.001 
  HADS (anxiety) 
 
-0.371 (0.172) -0.106 0.032 
  MSNSQ 
 
0.359 (0.049) 0.320 <0.001 
  FSS   2.780 (0.469) 0.248 <0.001 
 
Abbreviations: FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and 
Depression Scale; MFIS, Modified Fatigue Impact Scale; MS, Multiple Sclerosis; 
MSIS-29, Multiple Sclerosis Impact Scale-29; MSNSQ, Multiple Sclerosis 
Neuropsychological Screening Questionnaire 
 (a), Progressive MS; (b), Non-progressive MS 
* F(4,78)=65.4, p<0.001 
     † F(5, 219)=127, p<0.001 
      
 
